Co-expression of MET and CD47 is a novel prognosticator for survival of luminal-type breast cancer patients

Although luminal-type primary breast cancer can be efficiently treated, development of metastatic disease remains a significant clinical problem. We have previously shown that luminal-type circulating tumor cells (CTCs) co-expressing the tyrosine-kinase MET and CD47, a ligand involved in cancer cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Baccelli, Irène, Stenzinger, Albrecht, Vogel, Vanessa, Pfitzner, Berit Maria, Klein, Corinna, Wallwiener, Markus, Scharpff, Martina, Saini, Massimo, Holland-Letz, Tim, Sinn, Hans-Peter, Schneeweiss, Andreas, Denkert, Carsten, Weichert, Wilko, Trumpp, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226673/
https://www.ncbi.nlm.nih.gov/pubmed/25230070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226673/
https://www.ncbi.nlm.nih.gov/pubmed/25230070

Ejemplares similares